Implantable biosensor

• US 20060234369A1
• Filed: 11/08/2005
• Published: 10/19/2006
• Est. Priority Date: 04/14/2005
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Sih, Haris J.
• Application Number:
  US11/269,384
• Publication Number:
  US 20060234369A1
• Time in Patent Office: Days
• US Class Current: 435/287.100
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/05 Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves impedance plethysmography A61B5/0295; measuring movement of the entire body or parts thereof A61B5/11; detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof A61B5/24
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/413 Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
• CPC Class Codes: A61B 5/4519 Muscles A61B5/389, A61B5/224 take precedence

Abstract

The present invention provides implantable biosensors. The biosensors comprise tissue or cells which are electrically excitable or are capable of differentiating into electrically excitable cells, and which can be used to monitor the presence or level of a molecule in a physiological fluid. In one embodiment, the tissue or cells are coupled via an electrical interface to an electronic measuring device or an electronic amplifying device. The biosensors may be placed (inserted or implanted) in any animal including a mammal. The present invention also provides various methods which employ a biosensor of the invention.

Claims

1. An implantable biosensor comprising:

transgenic electrically excitable mammalian tissue or cells which are augmented with an expression cassette comprising a transcriptional regulatory element operably linked to an open reading frame encoding a protein which is capable of associating with the cell membrane and binding a molecule found in physiological fluid of a mammal, which binding alters the amount and/or activity of one or more intracellular second messenger molecules and which one or more intracellular second messenger molecules in turn modulate the activity of one or more ion channels, wherein the transgenic electrically excitable tissue or cells are optionally coupled via an electrical interface to an electronic measuring device or an electronic amplifying device.

2. The biosensor of claim 1 wherein the protein is a glucagon receptor, a receptor for a natriuretic peptide, an ion channel protein which binds ATP, an adrenergic receptor, a muscarinic receptor, an angiotensin receptor, or a vasopressin receptor.

3. The biosensor of claim 2 wherein the ion channel protein which binds ATP is an ATP-sensitive potassium channel protein.

4. The biosensor of claim 1 wherein the intracellular second messenger molecule is cAMP, cGMP, Ca²⁺, inositol triphosphate or diacylglycerol.

5. The biosensor of claim 1 wherein the transgenic electrically excitable mammalian tissue or cells further comprise a second expression cassette comprising a second transcriptional regulatory element operably linked to a second open reading frame encoding an ion channel protein.

6. The biosensor of claim 5 wherein the second expression cassette encodes a chloride channel protein or a nonselective cation channel protein.

7. The biosensor of claim 5 wherein the second transcriptional regulatory element is a promoter which is expressed in muscle cells.

8. The biosensor of claim 5 wherein the second open reading frame encodes an ion channel is sensitive to cAMP or cGMP.

9. The biosensor of claim 4 wherein the protein is a glucagon receptor and the binding of glucagon to the receptor increases the amount and/or activity of cAMP and/or cGMP.

10. The biosensor of claim 1 wherein the one or more ion channels include those associated with L-type Ca²⁺ current, K_r⁺ current, fast Na⁺ current and/or Cl⁻

current.

11. The biosensor donor of claim 1 wherein the transcriptional regulatory element is a promoter which is expressed in muscle cells.

12. The biosensor of claim 1 wherein the excitable tissue or cells are cardiac tissue or cells.

13. The biosensor of claim 1 wherein the transgenic mammalian tissue or cells are incorporated in an implantable device and/or a biocompatible matrix.

14. The biosensor of claim 13 wherein the device is a patch, tube, tubing, catheter, stent, wire, defibrillator, implantable drug infusion pump, wire leads, or pacemaker.

15. The biosensor of claim 1 which further comprises a drug delivery device.

16. A system, comprising:

transgenic mammalian cells which are electrically excitable or are capable of differentiating into electrically excitable cells, wherein the transgenic mammalian cells are augmented with an expression cassette comprising a transcriptional regulatory element operably linked to an open reading frame encoding a protein which is capable of associating with the cell membrane and binding a molecule found in physiological fluid of a mammal, which binding alters the amount and/or activity of one or more intracellular second messenger molecules and which one or more intracellular second messenger molecules in turn modulate the activity of one or more ion channels; and

an implantable medical device including;

an event detector electrically coupled to the transgenic mammalian cells and adapted to detect a modulation in conduction and/or refractoriness in the transgenic mammalian cells as a result of the binding of the molecule to the protein; and

an implant controller coupled to the event detector, the implant controller adapted to produce a signal in response to the modulation in the conduction and/or refractoriness detected by the event detector.

17. The system of claim 16 further comprising at least one lead coupled between the event detector and the transgenic mammalian cells, the at least one lead including one or more electrodes configured for placement in or on the transgenic mammalian cells.

18. The system of claim 17 wherein the implantable medical device further comprises a pacing circuit coupled to the implant controller, and wherein the implant controller includes a pacing control module adapted to control a delivery of pacing pulses.

19. The system of claim 18 wherein the implantable medical device further comprises an implant telemetry module to receive an external command, and wherein the pacing control module is adapted to produce an electrical signal in response to the external command.

20. The system of claim 19 further comprising an external system communicatively coupled to the implantable medical device, the external system including:

a user input device to produce the external command; and

an external telemetry module to transmit the external command to the implant telemetry module.

21. The system of claim 20 wherein the external system comprises a programmer.

22. The system of claim 21 wherein the external system comprises an advanced patient management system including:

an external device wirelessly coupled to the implantable medical device via telemetry;

a remote device to provide for access to the implantable medical device from a distant location; and

a network connecting the external device and the remote device.

23. The system of claim 22 wherein the external device comprises the user input.

24. The system of claim 22 wherein the remote device comprises the user input.

25. The system of claim 17 wherein the implantable medical device further comprises an implant telemetry module coupled to the implant controller and adapted to transmit the signal to an external system.

26. The system of claim 25 wherein the external system includes a user input device to receive the transmitted signal.

27. The system of claim 17 wherein a biocompatible matrix comprises the transgenic mammalian tissue or cells.

28. The system of claim 17 wherein the signal is an electrical signal.

29. The system of claim 17 further comprising a drug delivery device.

30. The system of claim 17 wherein the device is a patch, tube, tubing, catheter, stent, wire, defibrillator, implantable drug infusion pump, wire leads, or pacemaker.

31. A method comprising monitoring in a mammal having the system of claim 16 a signal produced by the implant controller.

32. A method of regulating delivery of an electrical signal in a mammal from an external system comprising:

monitoring the presence and/or amount of a molecule found in physiological fluid of a mammal having the system of claim 19, and regulating the electrical signal from the pacing control module in response to a modulation in the conduction and/or refractoriness of the transgenic electrically excitable mammalian tissue or cells.

33. The method of claim 32 wherein the transgenic electrically excitable tissue or cells are cardiac tissue or cells.

34. The method of claim 32 wherein the transgenic electrically excitable mammalian tissue or cells are incorporated in a biocompatible matrix.

35. The method of claim 32 wherein the implantable medical device further comprises a drug delivery device.

36. The system of claim 16 wherein the system comprises a tissue comprising the transgenic mammalian cells.